Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10373	Companies
216184	Keywords
145886	Articles
114463	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 12/15/2025 at 15:00, 4 months 25 days ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Jaguar Health announces submission of abstract detailing preliminary findings from clinical trial on a novel oral liquid formulation of crofelemer for SBS-IF patients, supporting the focus on reducing PS needs in intestinal failure patients

Crofelemer Jaguar Health Clinical Trial SBS-IF Intestinal Failure
BRIEF

published on 12/10/2025 at 15:05, 4 months 30 days ago

FDA Extends Conditional Approval for Jaguar Health's Canalevia-CA1

FDA Approval Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy In Dogs
BRIEF

published on 12/10/2025 at 15:05, 4 months 30 days ago

La FDA prolonge l'approbation conditionnelle du Canalevia-CA1 de Jaguar Health

Jaguar Health Canalevia-CA1 Approbation De La FDA Médecine Vétérinaire Chimiothérapie Chez Les Chiens
PRESS RELEASE

published on 12/10/2025 at 15:00, 4 months 30 days ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Health, Inc. (NASDAQ:JAGX) receives FDA renewal for Canalevia-CA1, a prescription drug for chemotherapy-induced diarrhea (CID) in dogs, with conditional approval extended until December 2026

Veterinary Medicine Jaguar Health Canalevia-CA1 Chemotherapy-induced Diarrhea FDA Renewal
BRIEF

published on 12/08/2025 at 22:20, 5 months 1 day ago

Jaguar Health annonce l'approbation de propositions lors de l'assemblée générale des actionnaires

Crofelemer Jaguar Health Approbation De La FDA Assemblée Générale Des Actionnaires Maladie À Inclusions Microvillositaires
BRIEF

published on 12/08/2025 at 22:20, 5 months 1 day ago

Jaguar Health Announces Approval of Proposals at Stockholder Meeting

Crofelemer Microvillus Inclusion Disease FDA Approval Jaguar Health Stockholder Meeting
PRESS RELEASE

published on 12/08/2025 at 22:15, 5 months 1 day ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders
Jaguar CEO Lisa Conte to present updates on near-term catalysts at Emerging Growth Conference; Initial results show crofelemer may extend infants' lives with MVID; Jaguar completes FDA meeting on crofelemer trial for MVID treatment

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference MVID
BRIEF

published on 12/02/2025 at 15:05, 5 months 7 days ago

Jaguar Health sollicite l'approbation de l'EMA pour Canalevia dans le traitement de la diarrhée canine

Jaguar Health Agence Européenne Des Médicaments Diarrhée Du Chien Approbation De Canalevia Traitement Non Antibiotique
BRIEF

published on 12/02/2025 at 15:05, 5 months 7 days ago

Jaguar Health Seeks EMA Approval for Canalevia to Treat Dog Diarrhea

Jaguar Health European Medicines Agency Dog Diarrhea Canalevia Approval Non-antibiotic Treatment
PRESS RELEASE

published on 12/02/2025 at 15:00, 5 months 7 days ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study
Jaguar Health, Inc. requests advice from EMA on EU approval pathway for Canalevia® in treating general diarrhea in dogs. Novel non-antibiotic approach targets a significant market gap

Jaguar Health Dogs EMA Canalevia General Diarrhea

Accesswire

Published on 05/09/2026 at 01:55, 1 day 12 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 13 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 13 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 14 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 15 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/10/2026 at 14:00, 43 minutes ago

MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 2 hours 58 minutes ago

Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 19 hours 38 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 18 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 19 hours ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026

Les Echos

Published on 05/07/2026 at 19:15, 2 days 19 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 19 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 19 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 19 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 19 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE